A5065885053- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Prostate Cancer Treatment and Research
- Cancer, Lipids, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Estrogen and related hormone effects
- Pharmacogenetics and Drug Metabolism
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Research Studies
- Radiopharmaceutical Chemistry and Applications
- Drug Transport and Resistance Mechanisms
- Chronic Lymphocytic Leukemia Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Intraperitoneal and Appendiceal Malignancies
- Glioma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Advanced Breast Cancer Therapies
- Chronic Myeloid Leukemia Treatments
- Cancer Genomics and Diagnostics
- Nanoparticle-Based Drug Delivery
- PI3K/AKT/mTOR signaling in cancer
- Cancer therapeutics and mechanisms
- Inflammatory mediators and NSAID effects
- Gastric Cancer Management and Outcomes
Erasmus MC
2017-2025
Erasmus MC Cancer Institute
2016-2025
Erasmus University Rotterdam
2019-2025
The Netherlands Cancer Institute
2009-2019
Utrecht University
2011-2019
Oncode Institute
2009-2019
Center for Translational Molecular Medicine
2019
Stichting Apotheek der Haarlemse Ziekenhuizen
2013
Slotervaartziekenhuis
2009-2012
Dutch Cancer Society
2012
Abstract Background In the past years, there has been a notable increase in interest regarding targeted alpha therapy using Ac-225, driven by observed promising clinical anti-tumor effects. As production and technology advanced, availability of Ac-225 is expected to near future, making treatment available patients worldwide. Main body can be labelled different biological vectors, whereby success developing radiopharmaceutical depends heavily on labelling conditions, purity radionuclide...
Tamoxifen is an estrogen-receptor (ER) antagonist, used as adjuvant treatment of ER-positive breast cancer. It converted by CYP2D6 into endoxifen, its most active metabolite. Patients with endoxifen plasma concentrations <16 nM face a higher risk recurrence. The use priori model-informed precision dosing (MIPD) may lead to faster target attainment and thus potentially improve patient outcomes. In total, 106 evaluable patients were prospectively included in this single-arm MIPD-intervention...
Background: Thyroid dysfunction is among the most common adverse effects during anti-programmed cell death 1 (PD-1) immunotherapy, and alongside correlations with elevated anti-thyroid antibodies (ATAb), studies have found survival. However, exact relations remain to be clarified. We, therefore, aimed at clarifying relationship between thyroid dysfunction, ATAbs, survival in anti-PD-1 treated cancer patients. Methods: We included 168 patients nonsmall-cell lung carcinoma, renal metastatic...
Sotorasib given after immunotherapy could put patients at increased risk of hepatotoxicity. Therefore, there is a need to gain insight into the potential correlation between anti-PD-(L)1 treatment, concentrations, sotorasib and incidence hepatotoxicity during sotorasib.
Tamoxifen, a cornerstone in the adjuvant treatment of estrogen receptor-positive breast cancer, significantly reduces cancer recurrence and mortality; however, its standard dose 20 mg daily presents challenges due to broad spectrum adverse effects, contributing high discontinuation rates. Dose reductions tamoxifen might be an option reduce treatment-related toxicity, but large randomized controlled trials investigating tolerability and, more importantly, efficacy low-dose setting are...
<h3>Background</h3> Nivolumab is administered in a weight-based or fixed-flat dosing regimen. For patients with non-small cell lung cancer (NSCLC), potential exposure-response relationship has recently been reported and may argue against the current strategies. The primary objectives were to determine nivolumab pharmacokinetics (PK) assess between drug clearance clinical outcome NSCLC, melanoma, renal (RCC). <h3>Methods</h3> In this prospective observational cohort study, individual...
Background A minority of patients with advanced non-small-cell lung cancer (NSCLC) benefit from treatment immune checkpoint inhibitors (ICIs). Ineffective effector function activated T and NK cells may lead to reduced tumor cell death, even when these are released their brake. Hence, in this study we aimed assess the association baseline serum granzyme B, as well germline variation GZMB gene, clinical outcome programmed death protein 1 (PD-1) blockade. Methods total 347 stage IV NSCLC who...
The development and full validation of a sensitive selective ultra-performance liquid chromatography/tandem mass spectrometry (UPLC–MS/MS) method are described for the simultaneous analysis afatinib, alectinib, crizotinib osimertinib in human lithium heparinized plasma. Afatinib-d6, crizotinib-d5 erlotinib-d6 were used as internal standards. Given osimertinib's instability plasma whole blood at ambient temperature, samples should be solely processed on ice (T = 0 °C). Chromatographic...
Recently, promising results of the antitumor effects were observed in patients with metastatic castration-resistant prostate cancer treated 177Lu-labeled PSMA-ligands. Radionuclide therapy efficacy may even be improved by using alpha emitter Ac-225. Higher is claimed due to high linear energy transfer specifically towards PSMA positive cells, causing more double-strand breaks. This study aims manufacture [225Ac]Ac-PSMA-I&T according good manufacturing practice guidelines for translation...
Background: Osimertinib is the cornerstone in treatment of epidermal growth factor receptor-mutated non-small cell lung cancer (NSCLC). Nonetheless, ±25% patients experience severe treatment-related toxicities. Currently, it impossible to identify at risk toxicity beforehand. Therefore, we aimed study relationship between osimertinib exposure and a safe toxic limit for preventive dose reduction. Methods: In this real-life prospective cohort study, with NSCLC treated were followed (grade ⩾3...
Treatment with PD-1 inhibitors can be hampered by severe auto-immune-related toxicities. Our objective was to identify single-nucleotide polymorphisms (SNPs) in genes previously associated auto-immunity, which are toxicities nivolumab-treated NSCLC patients. This order patients prone develop and gain more insight into the underlying pathobiology.We analysed 322 assessed association for seven SNPs four genes, considered contributors PD-1-directed T-cell responses, i.e., PDCD1, PTPN11, ZAP70...